



## Repare Therapeutics to Participate in Two Upcoming Investor Conferences

August 27, 2024

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Aug. 27, 2024-- Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the presentations are as follows:

### **Morgan Stanley 22<sup>nd</sup> Annual Global Healthcare Conference**

Fireside Chat

Date: Thursday, September 5, 2024

Time: 1:05 p.m. Eastern Time

Location: New York, NY

### **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference**

Company Overview

Date: Wednesday, September 11, 2024

Time: 9:00 a.m. Eastern Time

Location: New York, NY

A live webcast of the presentations can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for at least 30 days.

### **About Repare Therapeutics, Inc.**

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx<sup>®</sup> platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit [www.reparerx.com](http://www.reparerx.com) and follow @Reparerx on X (formerly Twitter) and LinkedIn.

SNIPRx<sup>®</sup> is a registered trademark of Repare Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240827041601/en/): <https://www.businesswire.com/news/home/20240827041601/en/>

### **Investor Relations & Media:**

Robin Garner

Vice President and Head of Investor Relations

Repare Therapeutics Inc.

[investor@reparerx.com](mailto:investor@reparerx.com)

Source: Repare Therapeutics Inc.